Reference : The use of mycophenolate mofetil in liver transplant recipients
Scientific journals : Article
Human health sciences : Anesthesia & intensive care
Human health sciences : Gastroenterology & hepatology
Human health sciences : Immunology & infectious disease
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Surgery
http://hdl.handle.net/2268/1142
The use of mycophenolate mofetil in liver transplant recipients
English
Detry, Olivier mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
De Roover, Arnaud mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Delwaide, Jean mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Meurisse, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > Chirurgicale abdominale]
Honore, Pierre mailto [Centre Hospitalier Universitaire de Liège - CHU > > Chirurgie abdominale- endocrinienne et de transplantation >]
Nov-2003
Expert Opinion on Pharmacotherapy
Ashley Publications Ltd
4
11
1949-1957
Yes (verified by ORBi)
International
1465-6566
London
[en] adult ; children ; immunosuppression ; kidney ; liver transplantation ; mycophenolate mofetil ; nephrotoxicity ; fescue therapy ; review ; side effects ; solid organ ; surgery ; therapy ; transplantation
[en] Mycophenolate mofetil is an important drug in the modern immunosuppressive arsenal. Mycophenolate mofetil is the semisynthetic morpholinoethyl ester of mycophenolate acid. Mycophenolate acid prevents T and B cell proliferation by specifically inhibiting a purine pathway required for lymphocyte division. This paper extensively reviews the experience of mycophenolate mofetil use in liver transplant recipients. In randomised trials, mycophenolate mofetil decreased the rate of acute rejection after liver transplantation, without a significant increase of septic complications. However, so far, there are no data indicating that mycophenolate mofetil increases liver transplant patient or graft survivals. Mycophenolate mofetil is interesting because of its particular side effects profile, which is very different from the other immunosuppressants. The absence of mycophenolate mofetil nephrotoxicity is of specific interest in liver recipients with impairment of renal function. The monitoring of mycophenolate acid area under the concentration time curve might be interesting to limit side effects and provide better clinical efficacy but the exact role of mycophenolate acid monitoring in liver recipients has yet to be further evaluated in large series.
Professionals ; Students
http://hdl.handle.net/2268/1142

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
ExpOpinion.2003.pdfPublisher postprint28.49 MBRequest copy
Restricted access
Proof.pdfAuthor postprint401.63 kBRequest copy
Open access
Exp.opinion.2003.pdfAuthor preprint226.6 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.